low-dose emicizumab prophylaxis in patients with severe hemophilia a
Published 1 year ago • 1.1K plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
2:15
emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia a
-
8:37
primary analysis of haven 7: emicizumab prophylaxis in infants with severe hemophilia a
-
6:11
haven 7: emicizumab prophylaxis for the treatment of infants with severe hemophilia a
-
1:43
the impact of emicizumab prophylaxis on caregivers' burden for patients with hemophilia a
-
4:18
haven 6: emicizumab prophylaxis in non-severe hemophilia a without fviii inhibitors
-
2:06
emicizumab prophylaxis in hemophilia a
-
4:01
emicizumab for hemophilia a: interim analysis of the real-world emiil study
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
3:16
identifying low- and high-risk aml
-
10:09
prophylaxis in hemophilia: past, present and future
-
7:56
guy young: fitusiran for hemophilia a and b with inhibitors
-
2:47
real-world data on the safety of emicizumab in patients with hemophilia a
-
1:43
the safety and efficacy of fitusiran prophylaxis in patients with hemophilia a and b
-
3:45
how emicizumab has changed hemophilia a management
-
0:42
quality of life with octocog alfa in patients with hemophilia a: read-out of the ahead study
-
2:49
haven-6 trial updates: emicizumab in non-severe hemophilia a
-
1:27
the impact of emicizumab on the hemophilia treatment landscape
-
2:40
the safety & efficacy of emicizumab in patients under 18 months with hemophilia a
-
2:27
the impact of hemophilia inhibitors on patient outcomes
-
1:05
promising antibodies being explored in hemophilia & a novel diagnostic tool for patients
-
1:25
the use of clonoseq to monitor mrd in patients with lbcl treated with axi-cel in zuma-7
-
3:04
fitusiran significantly reduces bleeding events in patients with hemophilia a or b, with inhibitors